



Notice of Quarterly Update Call

San Diego, California and Sydney, Australia (Wednesday 5 November 2014, AEDT) – REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”) will hold a conference call to provide an update on the Company’s operations and its business outlook, and to discuss the Company’s financial results through 30 September 2014. Robert Stockman, the Company’s Chairman and Chief Executive Officer, will host the call.

The call is scheduled for 9:00 a.m. AEDT on Wednesday, 12 November 2014 (which is 2:00 p.m. US PST on Tuesday, November 11, 2014) and may be accessed within Australia by dialing (02) 8223 9773 five minutes prior to the scheduled start time. Callers in the United States and Canada may access the call by dialing 1-877-312-5413. If you are asked to provide an access code, please spell out the word “REVA” to the operator and you will be connected promptly.

If you reside outside of Australia, the United States, or Canada, or if you prefer to access the audiocast through our website, please visit “Events & Presentations” under the “Investors” section of our website at www.revamedical.com, and click on the “listen to webcast” link. A replay of the audiocast will be available on our website after the call.

About REVA

REVA is a development stage medical device company located in San Diego, California, USA, that is focused on the development, testing, and eventual commercialization of its proprietary bioresorbable stents, which are called “scaffolds” because of their temporary nature. The Company’s scaffolds are being developed as an alternative to metal stents, which are small tube-like devices permanently implanted into an artery to treat coronary artery disease. Scaffolds provide restoration of blood flow, support the artery through the healing process, then disappear (or “resorb”) from the body over a period of time. This resorption allows the return of natural movement and function of the artery, a result not attainable with permanent metal stents. The Company has conducted clinical studies of its scaffold technologies; a total of 112 patients were enrolled in its most recent clinical trial in Australia, Brazil, Europe, and New Zealand, with enrollment completed during January 2014. The patients in this trial will be followed for a total of five years, with primary data to be obtained at nine and 12 months. The Company is now developing and testing its *Fantom*TM scaffold, with initial human implants planned for late 2014 at multiple centers in Brazil and Europe. The *Fantom* scaffold has been designed to offer distinct ease-of-use features including complete scaffold visibility under x-ray, expansion with one continuous inflation, no procedural time limitations, and standard storage and handling. REVA will require successful clinical results and regulatory approval before it can commercialize *Fantom* or any of its other products.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management. All statements that are not statements of historical fact, including those statements that address future operating performance and events or

HEAD OFFICE: 5751 Copley Drive, San Diego, CA 92111 • +1 (858) 966-3000 • +1 (858) 966-3099 (FAX) • www.revamedical.com

AUSTRALIAN OFFICE: Level 2, Suite 2, 175 Macquarie Street, Sydney, NSW 2000 • +61 2 9229 2700 • +61 9229 2727 (FAX)

ABN 146 505 777 • REVA Medical, Inc., is a foreign company incorporated in Delaware, USA, whose stockholders have limited liability

developments that we expect or anticipate will occur in the future, are forward-looking statements, such as those statements regarding our ability to raise financing to fund our operations on terms favorable to us or at all, our ability to obtain the regulatory approvals, our ability to timely and successfully complete our clinical trials, our ability to protect our intellectual property position, our ability to commercialize our products if and when approved, our ability to develop and commercialize new products, and our estimates regarding our capital requirements and financial performance, including profitability. You should not place undue reliance on these forward-looking statements. Although management believes these forward-looking statements are reasonable as and when made, forward-looking statements are subject to a number of risks and uncertainties that may cause our actual results to vary materially from those expressed in the forward-looking statements, including the risks and uncertainties that are described in the "Risk Factors" section of our Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (the "SEC") on March 17, 2014. Any forward-looking statements in this announcement speak only as of the date when made. REVA does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

United States**Investor & Media Enquiries:**

REVA Medical, Inc.
Cheryl Liberatore
Director, Investor Relations
+1 858-966-3045

Australia**Investor Enquiries:**

Inteq Limited
Kim Jacobs
+61 2 9229 2700

Australia**Media Enquiries:**

Buchan Consulting
Rebecca Wilson
+61 3 9866 4722
Annabel Murphy
+61 2 9237 2800